Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Altheia Science S.r.l.. (12/19/18). "Press Release: Altheia Science Announced the Final Closing of the Series A Capital Raise Banking $19.3M (€17M), Well Above the Initial Target of $11.4M (€10M)". Milano & New York, NY.

Organisations Organisation Altheia Science S.r.l.
  Organisation 2 AurorA-TT (IT)
Products Product gene expression technology
  Product 2 venture capital
Index term Index term Altheia Science–SEVERAL: investment, 201812 financing round Series A final closing €7.7m ($8.3m) bringing total round to €17m ($19.3m)
Person Person Rizzardi, Paolo (Alltheia Science 201809 CEO)
     


Altheia Science is Startup World Cup 2019 Italy Regional Champion and receives the 2018 Special Award Life Science at StartupItalia! Open Summit 2018


Altheia Science, a pioneering start-up focused on the development of curative and definitive medicines for autoimmune diseases and founded by two world renowned Italian scientists, Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD, together with AurorA-TT, a Technology Transfer Company based in Milano, announced today the closing of a Series A capital raise banking $19.3M (€17M). Investors include seasoned private players with successful track record in the biotech sector (key partners in Advanced Accelerator Applications), the Rovati family’s Fidim/Rottapharm Biotech group and Fin Posillipo SpA, holding company of Petrone Group.

Selected among the best 20 Italian startups participating to the Startup World Cup 2019 at StartupItalia! Open Summit 2018, held on December 17th in Milano, Altheia Science won the 1st prize becoming the Startup World Cup 2019 Italy Regional Champion. Altheia Science will thus compete in both the European Final (Prague, April 10th 2019) and the World Final (San Francisco, May 17th 2019). In addition, Altheia Science received the 2018 Special Award Life Science at StartupItalia! Open Summit 2018.

“The success of our fundraising campaign is unprecedented over a Series A in Italy and gives Altheia Science the means to rapidly translate its science into clinical trials in multiple sclerosis and type 1 diabetes” commented Paolo Rizzardi, MD, Chairman & Chief Executive Officer at Altheia Science. “And the awards we received at StartupItalia! Open Summit 2018 are an important recognition of the quality of our science and the value of our mission”.


About Altheia Science

Altheia Science (www.altheiascience.com) has been founded by Prof. Alessandra Biffi, MD and Prof. Paolo Fiorina, MD, PhD, together with the investment company AurorA-TT (www.aurora-tt.com). Altheia Science develops pioneering therapeutic tools for autoimmune diseases and cancer. The modulation of PD-L1 expression at the molecular and protein level is key to devise advanced treatments in autoimmune diseases and this can be achieved by first-in-class molecules controlling the PD-L1 pathway and/or by lentiviral vector-based engineering of patients’ hematopoietic stem cells.


About Alessandra Biffi

Alessandra Biffi, MD, is a pediatric hematologist and stem cell transplant physician with wide experience in gene therapy and translational medicine. She is the current Director of the Gene Therapy Program, Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, of the Program for Gene Therapy in Rare Diseases in the Department of Medicine of Boston Children’s Hospital, is the Faculty Director for Gene Therapy at Dana-Farber Cancer Institute, Principal Scientist at the Harvard Stem Cell Institute, Chair of the Scientific Review Committee for Gene Therapy at Boston Children’s Hospital, and Associate Professor of Pediatrics Harvard Medical School.

She published over 65 peer-reviewed manuscripts and textbook chapters (3076 citations, h index=25). She is actively involved in gene therapy trials for neurological genetic diseases, hemoglobinopathies and immunodeficiencies and has developed a unique expertise in the pre-clinical development and clinical testing of hematopoietic stem cell gene therapy approaches. Her publication track record includes seminal contribution to the field of cell and gene therapy.


About Paolo Fiorina

Paolo Fiorina, MD, PhD is an Immunologist, Internist and Associate Professor of Endocrinology. He is Director of the Romeo ed Enrica Invernizzi International Center for T1D at the University of Milan, Italy; Associate Professor of Endocrinology, L. Sacco Hospital, University of Milan; Chief of Endocrinology Division, ASST Sacco-Fatebenefratelli, Milan, Italy and Lecturer in Pediatrics, Boston Children’s Hospital, Harvard Medical School. He is actively involved in the Grant Committee of JDRF, American Diabetes Association (ADA), American Heart Association (AHA), and American Society of Transplantation (AST). He published over 155 peer-reviewed manuscripts (5700+ citations, h-index 45). He is focused in devising new immune-based preventive and therapeutic strategies for autoimmune diseases.


About AurorA-TT

AurorA-TT (www.aurora-tt.com) is a Technology Transfer Company established in 2017 based in Milan, Italy with the mission to identify promising scientific breakthroughs from academic and research centers in Italy and partner with academia, research institutions and biotech companies based globally.? AurorA-TT includes 5 co-founders with more than 115 years of cumulative experience and track record in technology transfer, venture capital, basic research, project/drug selection and development, market access and launch of pharmaceutical and biotechnology products, spanning from small molecules to advanced therapy medicinal products: Guido Guidi, MD, Chairman, former Head Pharma Region Europe Novartis; Paolo Rizzardi, MD, former General Manager MolMed SpA and Chairman & CEO Altheia Science; Pierluigi Paracchi, Chairman & CEO at Genenta Science and Corporate Consultant at Altheia Science; Gabriele Campi, PhD, former researcher, venture capitalist and technology transfer manager, Project Manager Altheia Science; Edoardo Negroni, MBA, entrepreneur in drug discovery and former pharma executive.


For further information:

Paolo Rizzardi, MD, Chairman & CEO
telephone: +39.335.193.5042
e-mail: paolo.rizzardi@altheiascience.com
web: www.altheiascience.com


Altheia Science S.r.l.
TOWARDS CURATIVE MEDICINE

IT Office:
Via Enrico Besana, 7
20122 – Milano (Italy)

US Office:
Empire State Building, 350 Fifth Avenue
Suite 7530, New York, NY 10118

C.F. / P.IVA 10128260964
e-mail: info@altheiascience.com
PEC: altheiascience@legalmail.it
web: www.altheiascience.com

   
Record changed: 2019-01-08

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Altheia Science S.r.l.


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSG] Life-Sciences-Germany.com – The Business Web Portal 600x80px




» top